AU2002254124A1 - Aryl-n-cyanoguanidines and methods related thereto - Google Patents
Aryl-n-cyanoguanidines and methods related theretoInfo
- Publication number
- AU2002254124A1 AU2002254124A1 AU2002254124A AU2002254124A AU2002254124A1 AU 2002254124 A1 AU2002254124 A1 AU 2002254124A1 AU 2002254124 A AU2002254124 A AU 2002254124A AU 2002254124 A AU2002254124 A AU 2002254124A AU 2002254124 A1 AU2002254124 A1 AU 2002254124A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- sub
- compounds
- cyanoguanidines
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004898 mitochondrial function Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27236801P | 2001-02-27 | 2001-02-27 | |
| US60/272,368 | 2001-02-27 | ||
| PCT/US2002/006717 WO2002068381A2 (en) | 2001-02-27 | 2002-02-27 | Aryl-n-cyanoguanidines and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002254124A1 true AU2002254124A1 (en) | 2002-09-12 |
Family
ID=23039505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002254124A Abandoned AU2002254124A1 (en) | 2001-02-27 | 2002-02-27 | Aryl-n-cyanoguanidines and methods related thereto |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6562821B2 (OSRAM) |
| EP (1) | EP1377282B1 (OSRAM) |
| JP (1) | JP2004525906A (OSRAM) |
| AT (1) | ATE336237T1 (OSRAM) |
| AU (1) | AU2002254124A1 (OSRAM) |
| CA (1) | CA2475454A1 (OSRAM) |
| DE (1) | DE60213958T2 (OSRAM) |
| ES (1) | ES2271247T3 (OSRAM) |
| WO (1) | WO2002068381A2 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60213958T2 (de) * | 2001-02-27 | 2007-08-30 | Migenix Corp., San Diego | Aryl-n-cyanoguanidine derivate und deren verwendung |
| US7411000B2 (en) * | 2001-03-15 | 2008-08-12 | The Scripps Research Institute | Process of inhibiting cell death in injured cartilage |
| WO2003050261A2 (en) * | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| US7642092B2 (en) * | 2003-03-03 | 2010-01-05 | Technion Research & Development Foundation Ltd. | Cultured cartilage/bone cells/tissue, method of generating same and uses thereof |
| WO2019151840A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4265905A (en) * | 1975-09-30 | 1981-05-05 | Merck & Co., Inc. | Method of treating inflammation employing acyl cyanoguanidines |
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| CA2404626A1 (en) * | 2000-03-31 | 2001-10-04 | Pfizer Products Inc. | Novel piperazine derivatives |
| DE60213958T2 (de) * | 2001-02-27 | 2007-08-30 | Migenix Corp., San Diego | Aryl-n-cyanoguanidine derivate und deren verwendung |
-
2002
- 2002-02-27 DE DE60213958T patent/DE60213958T2/de not_active Expired - Fee Related
- 2002-02-27 JP JP2002567895A patent/JP2004525906A/ja active Pending
- 2002-02-27 EP EP02723339A patent/EP1377282B1/en not_active Expired - Lifetime
- 2002-02-27 AU AU2002254124A patent/AU2002254124A1/en not_active Abandoned
- 2002-02-27 CA CA002475454A patent/CA2475454A1/en not_active Abandoned
- 2002-02-27 WO PCT/US2002/006717 patent/WO2002068381A2/en not_active Ceased
- 2002-02-27 AT AT02723339T patent/ATE336237T1/de not_active IP Right Cessation
- 2002-02-27 US US10/085,119 patent/US6562821B2/en not_active Expired - Fee Related
- 2002-02-27 ES ES02723339T patent/ES2271247T3/es not_active Expired - Lifetime
-
2003
- 2003-03-11 US US10/386,154 patent/US6927218B2/en not_active Expired - Fee Related
-
2005
- 2005-01-21 US US11/040,196 patent/US7230132B2/en not_active Expired - Fee Related
-
2007
- 2007-05-04 US US11/744,532 patent/US20080032981A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002068381A3 (en) | 2002-10-31 |
| US20080032981A1 (en) | 2008-02-07 |
| US20040067987A1 (en) | 2004-04-08 |
| US20030045556A1 (en) | 2003-03-06 |
| DE60213958T2 (de) | 2007-08-30 |
| CA2475454A1 (en) | 2002-09-06 |
| ATE336237T1 (de) | 2006-09-15 |
| JP2004525906A (ja) | 2004-08-26 |
| US6927218B2 (en) | 2005-08-09 |
| US20050182057A1 (en) | 2005-08-18 |
| EP1377282A2 (en) | 2004-01-07 |
| EP1377282B1 (en) | 2006-08-16 |
| DE60213958D1 (de) | 2006-09-28 |
| US7230132B2 (en) | 2007-06-12 |
| US6562821B2 (en) | 2003-05-13 |
| ES2271247T3 (es) | 2007-04-16 |
| WO2002068381A2 (en) | 2002-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| EA200200509A1 (ru) | Новые производные бензоимидазола, используемые в качестве антипролиферативного средства | |
| ATE260263T1 (de) | Heteroaromatische bizyklische verbindungen mit antikrebswirkung | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
| IL163629A0 (en) | Glutaminyl derivatives and pharmaceutical compositions containing the same | |
| EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
| WO2004056786A3 (en) | Pyrimidine derivates for the treatment of abnormal cell growth | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| WO2004045618A3 (de) | Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung | |
| SI1427708T1 (sl) | Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo | |
| BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| BR9408325A (pt) | Composto composição farmacêutica e processo para a manufatura de um composto | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| AU2246292A (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| SI1696905T1 (sl) | Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| EP1177791A3 (en) | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | |
| PL342614A1 (en) | Anticarcinogenic drugs | |
| MD1560F2 (en) | Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses. | |
| TR199701497T1 (xx) | Beyin �demini �nleyen terkip. | |
| AU2002254124A1 (en) | Aryl-n-cyanoguanidines and methods related thereto | |
| EP1253139A3 (en) | Multioligoanilinated fullerenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |